US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

HeartFlow Inc. (HTFL): Revenue Growth, Strong Margin Profile Highlights IPO Bull Case

HeartFlow Inc. (HTFL): Healthcare AI IPO Opens Strong, Trades Steady on Heavy Demand

HeartFlow Inc. (HTFL): Peeking at the IPO Prospectus of Coronary Artery Disease Patient Care Company

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Heartflow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion.</li>
<li>They expect revenue for the three months ended June 30, 2025 to be approximately $42.9 million to $43.4 million, as compared to $31.1 million for the same period in 2024.</li>
<li>Heartflow is scheduled to debut on Friday, August 8th. We anticipate the offering to be "well-received". </li>
</ul>


Heartflow is offering 12.5 million shares at a $15-$17 range which equates to a valuation of around $1.32 billion.
They expect revenue for the three months ended June 30, 2025 to be approximately $42.9 million to $43.4 million, as compared to $31.1 million for the same period in 2024.
Heartflow is scheduled to debut on Friday, August 8th. We anticipate the offering to be "well-received". 


ハートフロー社（HTFL）：冠動脈疾患治療会社が、評価額13億ドルを目指す条件を設定